The complaint filed against the biotechnology firm contends that former CEO Christopher Missling engaged in misconduct that remained undisclosed to the public. Plaintiffs allege that the company’s leadership provided materially false information about business operations, failing to account for significant regulatory challenges that ultimately impacted share value. The lawsuit claims that the firm’s internal controls were insufficient, rendering previous statements about its corporate prospects baseless.

Legal counsel represented by The Law Offices of Frank R. Cruz is inviting affected shareholders to review their options before the court-mandated deadline. While investors are not required to take immediate action to remain part of the class, those seeking a more active role in the litigation must file their intent by the end of November.